• Executive interview - Race Oncology

    682 views 2 years ago
    Race Oncology is developing bisantrene, which had been the subject of over 40 clinical trials in the 1980s and 1990s as part of Lederle’s search for a safer anthracycline chemotherapy. Despite positive responses in a variety of cancers, especially AML (it was even approved for the treatment of AML in France, but never commercialised), development stopped after Lederle was sold to Wyeth and then Wyeth to Pfizer. Race will be developing bisantrene initially for relapsed/refractory AML and expects to start a pivotal trial for approval in the US around the end of 2018. Show less
    Read more
  • Uploads Play all

    • Executive interview - VolitionRX discusses Q319 results and provides a business update - Duration: 7 minutes, 56 seconds.

      • 1 day ago
      • No views
      Volition is a multinational life sciences company developing simple, easy-to-use, cost-effective blood tests to help diagnose a range of cancers and other diseases in the human and animal health ma...
    • Executive interview Bragg Gaming Group - Duration: 4 minutes, 48 seconds.

      • 2 days ago
      CEO Dominic Mansour provides an introduction to Bragg Gaming – a fast-growing European online B2B casino operator. Revenue increased by 30% during Q319 and Bragg is now entering the US market throu...
    • Bitesize briefing – UK Southern North Sea - Duration: 6 minutes, 50 seconds.

      • 2 days ago
      In this video we look at recent activity in the UK Southern North Sea.

      See more at: https://www.edisongroup.com/our-content/
    • Bitesize briefing – Deutsche Beteiligungs - Duration: 3 minutes, 9 seconds.

      • 6 days ago
      In this video, Milosz Papst describes the company profile, portfolio and recent performance of Deutsche Beteiligungs, a Germany-based private equity investment and fund management company.

      See mor...
    • Bitesize briefing – BioPharma Credit - Duration: 4 minutes, 23 seconds.

      • 1 week ago
      In this video, Milosz Papst discusses the company profile, investment strategy and recent performance of BioPharma Credit, a leading lender in the life sciences space.

      See more at: https://www.edi...
    • Executive interview – Northbridge Industrial Services - Duration: 2 minutes, 20 seconds.

      • 2 weeks ago
      In this short video, Northbridge’s CEO Eric Hook introduces the company, explains how it has returned to profitability following the oil price downturn, how it is expanding its customer base across...
    • Executive interview – Duke Royalty Full - Duration: 4 minutes, 22 seconds.

      • 2 weeks ago
      In this interview Rael Sarembock, vice president of Duke Royalty, discusses the attractions of royalty finance versus other forms of financing and the investment criteria Duke looks for when making...
    • Edison sports investment conference 2019 - Duration: 47 seconds.

      • 3 weeks ago
      How to play the global sports opportunity

      On 8 October, Edison hosted its first ever sports conference explaining how sports and finance can combine in exciting ways. However, it was clear that so...
    • Fund manager interview: Polar Capital - Duration: 5 minutes, 3 seconds.

      • 3 weeks ago
      John Yakas, co-manager of Polar Capital Global Financials Trust (PCFT) discusses the improved fundamentals of the financial sector and strong income story as well as the sector’s historically attra...
    • Bitesize briefing: Recent exploration developments offshore Guyana, Mexico and Ireland - Duration: 5 minutes, 23 seconds.

      • 4 weeks ago
      This is the first in a series of videos looking at activities in the oil and gas sector with a particular focus on exploration. In this video we look at recent developments in Guyana, Mexico and th...
    • Executive interview – The Scottish Investment Trust - Duration: 7 minutes, 1 second.

      • 1 month ago
      The Scottish Investment Trust adopts a contrarian approach to investing in companies around the world, seeking to ignore the ‘madness of crowds’ and instead invest in deeply unloved areas of the st...
    • Executive interview - RhoVac - Duration: 3 minutes, 18 seconds.

      • 1 month ago
      RhoVac is developing RV001, a cancer immunotherapy designed to prevent or limit metastasis by activating T-cells against cells with metastatic potential. The therapy contains fragments of the prote...
    This item has been hidden
  • This item has been hidden
to add this to Watch Later

Add to

Loading playlists...